ReviewFrontiers in oncology2024
Current therapies and progress in the treatment of advanced gastric cancer.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 20 citations in OpenAlex.
- Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-positive advanced or metastatic gastric or gastroesophageal cancer: a meta-analysis of single-arm trials.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Phosphatidylserine Decarboxylase Promotes Ferroptosis Through STAT3/GPX4 Signaling in Gastric Cancer.Current issues in molecular biology · 2026Article
- Integrative analysis of immune and microbial subtypes predicts immunotherapy response in stomach adenocarcinoma.Microbiology spectrum · 2026Article
- Unlocking the potential: current landscape and future directions of immunotherapy in gastric cancer.Frontiers in immunology · 2026Review
- Revisiting gastric cancer disparities in Asian American subgroups: insights from the SEER database.Frontiers in oncology · 2026Article
- Efficacy and Safety of Different Treatment Regimens for Previously Untreated Patients with HER2-positive Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials.Journal of gastrointestinal cancer · 2025Review
- USP4-Mediated deubiquitination of A2AR suppresses autophagy-dependent ferroptosis in gastric cancer.Cellular and molecular life sciences : CMLS · 2025Article
- Porphyrinic MOF-derived novel nanocomposite for gastric anticancer and Helicobacter pylori photoantibacterial effect assay.Scientific reports · 2025Article
- Integrating single-cell and bulk RNA sequencing data to construct a pyroptosis-related prognostic signature and analyze the tumor microenvironment in gastric cancer.Translational cancer research · 2025Article
- Exploring the Shared miRNA-mRNA Signature Network Between Helicobacter pylori Infection and Gastric Cancer: A Comparative Study.Current microbiology · 2025Article
- Paraoxonase 1 polymorphisms and their relationship with gastric cancer risk: a biochemical perspective on oxidative stress.Molecular biology reports · 2025Article
- Astaxanthin in cancer therapy and prevention (Review).Biomedical reports · 2025Review
- STX1A regulates ferroptosis and chemoresistance in gastric cancer through mitochondrial function modulation.Human cell · 2025Article
- Acute compartment syndrome due to skeletal muscle metastases from poorly differentiated upper gastrointestinal adenocarcinoma: a case report.World journal of surgical oncology · 2025Article
- The Role of UFMylation in the Development and Progression of Gastric Cancer.Oncology research · 2025Review
- Pathologic complete response after Sintilimab combined with FOLFOX therapy in MSI-H type patients with locally advanced GC: a case report.Frontiers in oncology · 2025Article
- The potential role of rutin, a flavonoid, in the management of cancer through modulation of cell signaling pathways.Open life sciences · 2025Review
- Pan-gastrointestinal adenocarcinoma analysis uncovers the prognostic and immune correlates of ferroptosis-related genes.Translational gastroenterology and hepatology · 2025Article
- Prognostic Influence of Galectin-1 in Gastric Adenocarcinoma.Biomedicines · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) remains one of the most life-threatening disease worldwide with poor prognosis because of the absence of effective treatment and the delay in diagnosis. Due to the delay of diagnosis, a large proportion of GC patients are diagnosed as advanced GC, with extreme short lifespan. In the past few years, some pivotal progress and novel therapies was proposed, and conducted into clinical researches and practice. In this study, we summarized the development of several novel immunotherapy or targeted treatment modalities for advanced GC, including immune checkpoint inhibitors, anti-angiogenic therapy and cancer vaccines. Additionally, the advantage and potential weakness in each of these therapeutic methods are also listed. Finally, we discussed the promising research direction of advanced GC treatment, and the limitation in basic and clinical research of advanced GC, including the combination of immunotherapy and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.